{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:04:07Z","timestamp":1785009847217,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007188","name":"Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.molmed.2026.06.014","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:26:34Z","timestamp":1784924794000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming rabies immune evasion via monoclonal antibody therapeutics"],"prefix":"10.1016","author":[{"given":"Md Jashim","family":"Uddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-3507","authenticated-orcid":false,"given":"Brian C.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.06.014_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101204","article-title":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","volume":"53","author":"de Melo","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag368","article-title":"Comparative long-term immunogenicity and boosting of 3-versus 4-session intradermal rabies post-exposure prophylaxis regimens, Cambodia and Madagascar: the Resist-3 study","author":"Parize","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1010071","article-title":"United Against Rabies Forum: the first 2 years","volume":"11","author":"Tidman","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.molmed.2026.06.014_bb0020","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018-recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0025","series-title":"Fields Virology: RNA Viruses","first-page":"338","article-title":"Rhabdoviridae","volume":"3","author":"Whelan","year":"2022"},{"key":"10.1016\/j.molmed.2026.06.014_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786953","article-title":"Lyssaviruses and the fatal encephalitic disease rabies","volume":"12","author":"Scott","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.05.066","article-title":"A phase 2b, randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies","volume":"42","author":"Quiambao","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0040","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","article-title":"A phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinrabTM) against human rabies immunoglobulin (HRIG)","volume":"73","author":"Kansagra","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186063","article-title":"Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy","volume":"14","author":"Zorzan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0055","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0060","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","article-title":"Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018","volume":"37","author":"Sreenivasan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(25)00735-4","article-title":"Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial","volume":"406","author":"Kulkarni","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2026.06.014_bb0070","volume":"61","author":"Liu","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41541-025-01109-w","article-title":"Safety and tolerability of a novel monoclonal antibody cocktail for rabies post-exposure prophylaxis","volume":"10","author":"Fotedar","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.molmed.2026.06.014_bb0080","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.46234\/ccdcw2025.209","article-title":"Efficacy evaluation of virus clearance of SYN023 in a murine rabies model\u2014China, 2025","volume":"7","author":"Yixiang","year":"2025","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.molmed.2026.06.014_bb0085","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216394","article-title":"mAb therapy controls CNS-resident lyssavirus infection via a CD4 T cell-dependent mechanism","volume":"15","author":"Mastraccio","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2516465122","article-title":"A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies","volume":"122","author":"Ren","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.06.014_bb0095","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012628","article-title":"A combination of two human monoclonal antibodies cures symptomatic rabies","volume":"12","author":"de Melo","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0100","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001689","article-title":"ICTV virus taxonomy profile: Rhabdoviridae 2022","volume":"103","author":"Walker","year":"2022","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0042-6822(90)90433-R","article-title":"Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19","volume":"175","author":"Conzelmann","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.molmed.2026.06.014_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.736114","article-title":"Structural and evolutionary insights into the binding of host receptors by the rabies virus glycoprotein","volume":"11","author":"Khalifa","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0115","first-page":"82","article-title":"Rabies virus receptors","volume":"11","author":"Lafon","year":"2005","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007189","article-title":"Metabotropic glutamate receptor subtype 2 is a cellular receptor for rabies virus","volume":"14","author":"Wang","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2026.06.014_bb0125","first-page":"e01611","article-title":"Transferrin receptor protein 1 cooperates with mGluR2 to mediate the internalization of rabies virus and SARS-CoV-2","volume":"97","author":"Wang","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"Fisher","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0135","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/acem.14755","article-title":"Rabies postexposure prophylaxis: what the U.S. emergency medicine provider needs to know","volume":"30","author":"Gibbons","year":"2023","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ame2.12273","article-title":"Regulation of innate immune responses by rabies virus","volume":"5","author":"Zhang","year":"2022","journal-title":"Animal Model Exp. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0145","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3390\/v16111774","article-title":"The immune escape strategy of rabies virus and its pathogenicity mechanisms","volume":"16","author":"Kiflu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.molmed.2026.06.014_bb0150","doi-asserted-by":"crossref","first-page":"10063","DOI":"10.1128\/JVI.79.15.10063-10068.2005","article-title":"Degeneration of neuronal processes after infection with pathogenic, but not attenuated, rabies viruses","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008343","article-title":"Novel role of SARM1 mediated axonal degeneration in the pathogenesis of rabies","volume":"16","author":"Sundaramoorthy","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2026.06.014_bb0160","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1292\/jvms.66.539","article-title":"Immunohistochemical localization of endothelial and inducible nitric oxide synthase within neurons of cattle with rabies","volume":"66","author":"Shin","year":"2004","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.molmed.2026.06.014_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.730892","article-title":"Early transcriptional changes in rabies virus-infected neurons and their impact on neuronal functions","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2020.108699","article-title":"SNAP25 regulates the release of the rabies virus in nerve cells via SNARE complex-mediated membrane fusion","volume":"245","author":"Yin","year":"2020","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013630","article-title":"Disparities in global rabies burden from GBD 2021: children, older adults, and low-SDI countries at continued risk","volume":"19","author":"Yang","year":"2025","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0180","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.06.014_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1273604","article-title":"Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection","volume":"14","author":"Mihaescu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","article-title":"The role of inflammasomes in human diseases and their potential as therapeutic targets","volume":"9","author":"Yao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.06.014_bb0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.06.014_bb0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41419-023-05749-5","article-title":"Influenza viral matrix 1 protein aggravates viral pathogenicity by inducing TLR4-mediated reactive oxygen species production and apoptotic cell death","volume":"14","author":"Kim","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2022.106589","article-title":"Effect of inhibition of Toll-like receptor 3 signaling on pathogenesis of rabies virus in mouse model","volume":"234","author":"Sardana","year":"2022","journal-title":"Acta Trop."},{"key":"10.1016\/j.molmed.2026.06.014_bb0210","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.106443","article-title":"Toll-like receptors (TLRs) in the trained immunity era","volume":"14","author":"Alexopoulou","year":"2025","journal-title":"Elife"},{"key":"10.1016\/j.molmed.2026.06.014_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000315","article-title":"Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies","volume":"5","author":"M\u00e9nager","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2026.06.014_bb0220","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.3390\/ijms25179144","article-title":"Rabies virus regulates inflammatory response in BV-2 cells through activation of Myd88 and NF-\u03baB signaling pathways via TLR7","volume":"25","author":"Xie","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2026.06.014_bb0225","doi-asserted-by":"crossref","first-page":"e00111","DOI":"10.1128\/JVI.00111-20","article-title":"Dual role of Toll-like receptor 7 in the pathogenesis of rabies virus in a mouse model","volume":"94","author":"Luo","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2024.105321","article-title":"Comparative analysis of rabies pathogenic and vaccine strains detection by RIG-I-like receptors","volume":"26","author":"Aouadi","year":"2024","journal-title":"Microbes Infect."},{"key":"10.1016\/j.molmed.2026.06.014_bb0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/ijmm.2025.5489","article-title":"NLRP3 inflammasome in health and disease (Review)","volume":"55","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0240","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1128\/JVI.00203-13","article-title":"Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1\u03b2 release in murine dendritic cells","volume":"87","author":"Lawrence","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2023.109708","article-title":"Interleukin-1\u03b2 suppresses rabies virus infection by activating cGAS-STING pathway and compromising the blood-brain barrier integrity in mice","volume":"280","author":"Wu","year":"2023","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323823","article-title":"Rabies vaccination induces a CD4+ TEM and CD4+CD8+ TEMRA TH1 phenotype in dogs","volume":"20","author":"Lang","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2026.06.014_bb0255","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JVI.02092-14","article-title":"The inability of wild-type rabies virus to activate dendritic cells is dependent on the glycoprotein and correlates with its low level of the de novo-synthesized leader RNA","volume":"89","author":"Yang","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0260","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.06.014_bb0265","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.06.014_bb0270","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/jir.2022.0117","article-title":"Exposing the two contrasting faces of STAT2 in inflammation","volume":"42","author":"Duodu","year":"2022","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.molmed.2026.06.014_bb0275","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/ijms23084095","article-title":"STAT1 and its crucial role in the control of viral infections","volume":"23","author":"Tolomeo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2026.06.014_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116159","article-title":"Human brain cell types shape host-rabies virus transcriptional interactions revealing a preexisting pro-viral astrocyte subpopulation","volume":"44","author":"Feige","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.06.014_bb0285","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1128\/JVI.79.12.7673-7681.2005","article-title":"Identification of the rabies virus alpha\/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3","volume":"79","author":"Brz\u00f3zka","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111949","article-title":"Rabies virus P protein binds to TBK1 and interferes with the formation of innate immunity-related liquid condensates","volume":"42","author":"Scrima","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.06.014_bb0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41467-017-00102-9","article-title":"Negri bodies are viral factories with properties of liquid organelles","volume":"8","author":"Nikolic","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.06.014_bb0300","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2010.09.016","article-title":"Amino acids at positions 273 and 394 in rabies virus nucleoprotein are important for both evasion of host RIG-I-mediated antiviral response and pathogenicity","volume":"155","author":"Masatani","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.molmed.2026.06.014_bb0305","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1128\/JVI.02220-09","article-title":"Rabies virus nucleoprotein functions to evade activation of the RIG-I-mediated antiviral response","volume":"84","author":"Masatani","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114478","article-title":"Lyssavirus matrix protein inhibits NLRP3 inflammasome assembly by binding to NLRP3","volume":"43","author":"Sui","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.06.014_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003060","article-title":"RelAp43, a member of the NF-\u03baB family involved in innate immune response against lyssavirus infection","volume":"8","author":"Luco","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2026.06.014_bb0320","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1128\/JVI.01930-06","article-title":"The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1","volume":"81","author":"Vidy","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.ads2210","article-title":"Structural analysis reveals how tetrameric tyrosine-phosphorylated STAT1 is targeted by the rabies virus P-protein","volume":"18","author":"Sugiyama","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.molmed.2026.06.014_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01125-22","article-title":"Substitution of S179P in the lyssavirus phosphoprotein impairs its interferon antagonistic function","volume":"96","author":"Wang","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0335","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1038\/s41598-019-48507-4","article-title":"Lyssavirus matrix protein cooperates with phosphoprotein to modulate the Jak-Stat pathway","volume":"9","author":"Sonthonnax","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.06.014_bb0340","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0300-9084(03)00137-8","article-title":"Apoptosis and rabies virus neuroinvasion","volume":"85","author":"Baloul","year":"2003","journal-title":"Biochimie"},{"key":"10.1016\/j.molmed.2026.06.014_bb0345","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1128\/JVI.77.19.10537-10547.2003","article-title":"Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis","volume":"77","author":"Pr\u00e9haud","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0350","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yexcr.2016.07.008","article-title":"Rabies virus matrix protein induces apoptosis by targeting mitochondria","volume":"347","author":"Zan","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.molmed.2026.06.014_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.144398","article-title":"Dynamic bidirectional regulation between Stk38 and rabies virus M protein coordinates apoptosis progression during neurotropic infection","volume":"315","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.molmed.2026.06.014_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijidoh.2023.100006","article-title":"Rabies post-exposure prophylaxis delivery to ensure treatment efficacy and increase compliance","volume":"1","author":"Nadal","year":"2023","journal-title":"IJID One Health"},{"key":"10.1016\/j.molmed.2026.06.014_bb0365","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/S1473-3099(22)00641-7","article-title":"Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures","volume":"23","author":"Whitehouse","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009878","article-title":"Evaluating surveillance for and estimating administration of rabies postexposure prophylaxis in the United States, 2012-2018","volume":"15","author":"Whitehouse","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0375","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2026.06.014_bb0380","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2026.06.014_bb0385","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.str.2024.10.002","article-title":"Structural insight into rabies virus neutralization revealed by an engineered antibody scaffold","volume":"32","author":"Kedari","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.molmed.2026.06.014_bb0390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2460\/javma.256.1.77","article-title":"Evaluation of species identification and rabies virus characterization among bat rabies cases in the United States","volume":"256","author":"Pieracci","year":"2020","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.molmed.2026.06.014_bb0395","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2460\/javma.258.11.1205","article-title":"Rabies surveillance in the United States during 2019","volume":"258","author":"Ma","year":"2021","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.molmed.2026.06.014_bb0400","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1038\/s41598-022-13527-0","article-title":"A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis","volume":"12","author":"Ejemel","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.06.014_bb0405","first-page":"48","article-title":"In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse North American bat rabies virus variants","volume":"2","author":"Franka","year":"2017","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107383","article-title":"Developing a human monoclonal antibody combination CRM25 to prevent rabies after exposure","volume":"64","author":"Long","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.molmed.2026.06.014_bb0415","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0420","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1093\/cid\/ciaf157","article-title":"Demise of the Milwaukee protocol for rabies","volume":"81","author":"Jackson","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2026.06.014_bb0425","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"De Benedictis","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2026.06.014_bb0430","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.06.014_bb0435","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/v13030391","article-title":"Isolation and characterization of cross-reactive human monoclonal antibodies that potently neutralize Australian bat lyssavirus variants and other phylogroup 1 lyssaviruses","volume":"13","author":"Weir","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.molmed.2026.06.014_bb0440","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.molmed.2026.06.014_bb0445","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.chom.2025.04.018","article-title":"Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations","volume":"33","author":"Aditham","year":"2025","journal-title":"Cell Host Microbe"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142600167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142600167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:57:47Z","timestamp":1785009467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149142600167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":89,"alternative-id":["S147149142600167X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.06.014","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming rabies immune evasion via monoclonal antibody therapeutics","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}